Buprenorphine: Difference between revisions
From IDWiki
(→: added Canadian guidelines) |
(added small periop section) |
||
Line 1: | Line 1: | ||
− | == |
+ | ==Background== |
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
+ | |||
⚫ | |||
⚫ | |||
+ | |||
⚫ | |||
{| class="wikitable" |
{| class="wikitable" |
||
− | ! |
+ | !Day!!Buprenorphine!!Opioid |
|- |
|- |
||
− | | |
+ | |—||—||stop to ensure withdrawal ([[COWS]] ≥12) |
|- |
|- |
||
− | | |
+ | |1||2 to 4 mg + 2 mg q1h prn (max 12 mg)||none |
|- |
|- |
||
− | | |
+ | |2||dose from yesterday + 2 mg q1h prn (max 16 mg)||none |
|} |
|} |
||
− | === |
+ | ===Microdosing Protocol=== |
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
+ | |||
⚫ | |||
{| class="wikitable" |
{| class="wikitable" |
||
− | ! |
+ | !Day!!Burprenorphine!!Short-acting opioid |
|- |
|- |
||
− | | |
+ | |1||0.5 mg||maintain |
|- |
|- |
||
− | | |
+ | |2||1 mg||maintain |
|- |
|- |
||
− | | |
+ | |3||1.5 mg||maintain |
|- |
|- |
||
− | | |
+ | |4||2 mg||maintain |
|- |
|- |
||
− | | |
+ | |5||2.5 mg||maintain |
|- |
|- |
||
− | | |
+ | |6||3 mg||maintain |
|- |
|- |
||
− | | |
+ | |7||4 mg + 2 mg q1h prn (max 12 mg)||stop |
|} |
|} |
||
− | ==== |
+ | ====Moderate==== |
{| class="wikitable" |
{| class="wikitable" |
||
− | ! |
+ | !Day!!Burprenorphine!!Short-acting opioid |
|- |
|- |
||
− | | |
+ | |1||0.5 mg daily||maintain |
|- |
|- |
||
− | | |
+ | |2||0.5 mg bid||maintain |
|- |
|- |
||
− | | |
+ | |3||1 mg bid||maintain |
|- |
|- |
||
− | | |
+ | |4||2 mg bid||maintain |
|- |
|- |
||
− | | |
+ | |5||3 mg bid||maintain |
|- |
|- |
||
− | | |
+ | |6||4 mg bid||maintain |
|- |
|- |
||
− | | |
+ | |7||5 mg bid||maintain |
|- |
|- |
||
− | | |
+ | |8||12 mg daily||stop |
|} |
|} |
||
− | ==== |
+ | ====Rapid==== |
{| class="wikitable" |
{| class="wikitable" |
||
− | ! |
+ | !Day!!Burprenorphine!!Short-acting opioid |
|- |
|- |
||
− | | |
+ | |1||0.5 mg q4h x4||maintain |
|- |
|- |
||
− | | |
+ | |2||1 mg q4h x4||maintain |
|- |
|- |
||
− | | |
+ | |3||2 mg q4h x4||maintain |
|- |
|- |
||
− | | |
+ | |4||4 mg q4h x4||stop |
|- |
|- |
||
− | | |
+ | |5||16 mg daily + 2 mg prn||stop |
|} |
|} |
||
− | ==== |
+ | ====Ultra-rapid==== |
{| class="wikitable" |
{| class="wikitable" |
||
− | ! |
+ | !Day!!Burprenorphine!![[Hydromorphone]] |
|- |
|- |
||
− | | |
+ | |1||0.5 mg q3h (max 2.5 mg)||3 mg po q4h + 2-4 mg po q4h prn |
|- |
|- |
||
− | | |
+ | |2||1 mg q3h (max 8 mg)||3 mg po q4h + 2-4 mg po q4h prn |
|- |
|- |
||
− | | |
+ | |3||12 mg daily||stop |
|} |
|} |
||
− | == |
+ | === Perioperative management === |
+ | |||
⚫ | |||
+ | * Consider tapering to 12 mg daily 2 to 3 days prior to surgery, or as low as 8 mg if a large or painful surgery |
||
⚫ | |||
+ | * For the surgery itself, use NSAIDs, [[fentanyl]], regional blocks, adjuncts, and non-pharmacologic options |
||
⚫ | |||
+ | * Post-op, resume original dose as soon as possible, possibly split bid to tid to optimize for pain control, and continue non-buprenorphine pain management, including full agonist opioids if needed |
||
+ | |||
+ | ==Further Reading== |
||
+ | |||
⚫ | |||
⚫ | |||
⚫ | |||
[[Category:Opioid substitution therapy]] |
[[Category:Opioid substitution therapy]] |
Revision as of 20:08, 9 July 2020
Background
- Recommended as first-line treatment for opioid use disorder in Canadian guidelines
- Typically coformulated with naloxone (trade name Suboxone) at a dose of 2 mg buprenorphine to 0.5 mg naloxone
- Buprenorphine is partial μ-opioid receptor agonist
- Strong receptor affinity, displaces other opioids and can precipitate withdrawal
- Theoretical ceiling effect on side effects
Dosing
Standard Induction Protocol
- It's use can precipitate withdrawal, so wait 12-24h after short-acting opioids, 18-36h after long-acting, or after tapering methadone, before starting buprenorphine
Day | Buprenorphine | Opioid |
---|---|---|
— | — | stop to ensure withdrawal (COWS ≥12) |
1 | 2 to 4 mg + 2 mg q1h prn (max 12 mg) | none |
2 | dose from yesterday + 2 mg q1h prn (max 16 mg) | none |
Microdosing Protocol
- Suboxone combined with a short-acting opioid such as hydromorphone
- In general, all opioids can be stopped once at a dose of buprenorphine 12 mg daily
Standard
Day | Burprenorphine | Short-acting opioid |
---|---|---|
1 | 0.5 mg | maintain |
2 | 1 mg | maintain |
3 | 1.5 mg | maintain |
4 | 2 mg | maintain |
5 | 2.5 mg | maintain |
6 | 3 mg | maintain |
7 | 4 mg + 2 mg q1h prn (max 12 mg) | stop |
Moderate
Day | Burprenorphine | Short-acting opioid |
---|---|---|
1 | 0.5 mg daily | maintain |
2 | 0.5 mg bid | maintain |
3 | 1 mg bid | maintain |
4 | 2 mg bid | maintain |
5 | 3 mg bid | maintain |
6 | 4 mg bid | maintain |
7 | 5 mg bid | maintain |
8 | 12 mg daily | stop |
Rapid
Day | Burprenorphine | Short-acting opioid |
---|---|---|
1 | 0.5 mg q4h x4 | maintain |
2 | 1 mg q4h x4 | maintain |
3 | 2 mg q4h x4 | maintain |
4 | 4 mg q4h x4 | stop |
5 | 16 mg daily + 2 mg prn | stop |
Ultra-rapid
Day | Burprenorphine | Hydromorphone |
---|---|---|
1 | 0.5 mg q3h (max 2.5 mg) | 3 mg po q4h + 2-4 mg po q4h prn |
2 | 1 mg q3h (max 8 mg) | 3 mg po q4h + 2-4 mg po q4h prn |
3 | 12 mg daily | stop |
Perioperative management
- Consider tapering to 12 mg daily 2 to 3 days prior to surgery, or as low as 8 mg if a large or painful surgery
- For the surgery itself, use NSAIDs, fentanyl, regional blocks, adjuncts, and non-pharmacologic options
- Post-op, resume original dose as soon as possible, possibly split bid to tid to optimize for pain control, and continue non-buprenorphine pain management, including full agonist opioids if needed
Further Reading
- Management of opioid use disorders: a national clinical practice guideline. CMAJ. 2018;190(9):E247-E257. doi: 10.1503/cmaj.170958
- Opioid Enabler cheat sheet from Portico Network
- Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method. Subst Abuse Rehabil. 2016; 7: 99–105. doi: 10.2147/SAR.S109919